A retrospective analysis was performed on 100 patients with non-Hodgkin's lymphoma (NHL, n = 75) or Hodgkin's disease (HD, n = 25) who underwent peripheral blood progenitor cell transplant (PBPCT) following high-dose chemotherapy (HDCT) with BCNU, etoposide, cytarabine and melphalan (BEAM) between March 1994 and June 1997. Following PBPCT and until engraftment all patients received oral ciprofloxacin and fluconazole, patients with positive Herpes simplex virus serology received acyclovir and 91 patients received filgrastim. The median days of neutropenia and days to an absolute neutrophil count (ANC) Ͼ500/mm 3 were 6 and 9, respectively. Febrile neutropenia occurred in 68 patients. Gram-positive bacteremia occurred in 14 patients. No gram-negative infections, invasive fungal infections, intensive care visits or deaths occurred during the period of neutropenia or in the first 30 days following transplant. In multivariate logistic regression the risk of development of any infection was associated only with the duration of neutropenia (P = 0.02) and the risk of bacteremia was associated only with the number of CD34
receiving HDCT. In comparison with autologous bone marrow, PBPC support following high-dose chemotherapy results in a quicker time to engraftment of white blood cells and platelets and is associated with reductions in the use of blood products, shorter hospital stays and lower costs. 1, 2 Despite these advances, patients receiving myeloablative chemotherapy with PBPC support have profound and occasionally prolonged neutropenia, remaining at risk for the development of serious infections, prolonged hospitalization, morbidity and mortality.
PBPC support has also been associated with a more favorable profile of infectious complications post-transplant, when retrospectively compared to marrow, primarily because the duration of neutropenia is reduced when PBPC are employed. 3, 4 A number of other variables have the potential to affect the risk, as well as the spectrum of infections post-transplant, including patient population treated, conditioning regimen employed, number of CD34 + cells infused and supportive care measures used post-transplant, such as prophylactic antibiotics and hematopoietic growth factors. The role these factors play with regard to infectious outcome is not well defined.
Few studies of infectious complications following HDCT with PBPC support have been reported and most have included heterogeneous patient populations treated with a variety of conditioning regimens. We have conducted a retrospective study of infectious complications occurring during the period of neutropenia in 100 patients with Hodgkin's disease (HD) and non-Hodgkin's lymphoma (NHL) treated over a 3-year period with high-dose BEAM chemotherapy supported with PBPC, filgrastim and a uniform prophylactic antibiotic strategy.
Patients and methods

Patients
Inpatient and outpatient medical records of all patients with HD and NHL undergoing high-dose chemotherapy with PBPC support in the Yale Section of Medical Oncology between March 1994 and June 1997 were reviewed. One hundred patients with NHL and HD underwent high-dose chemotherapy with BEAM followed by PBPC transplant during this time period. No patients received alternative conditioning regimens or autologous marrow transplantation in our department during this time period. Patient characteristics are presented in Table 1 . The majority of patients with NHL were treated in chemotherapy-sensitive relapse or in first complete/partial remission for high-risk disease. Nine patients were treated with primary resistant or relapsed resistant disease. Two patients with NHL received syngeneic stem cell rescue. One patient received sequential transplants with identical doses of BEAM and two patients received BEAM and PBPC rescue as the second of sequen- + cells/kg infused, dose of filgrastim post-transplant, days of neutropenia, days to WBC engraftment, days of fever, days of hospitalization, days in intensive care, antibiotic therapy, culture results, and mortality at day 30 and day 100. Patients referred to the center by community physicians were frequently treated with mobilizing chemotherapy by the referring physician following initial consultation. Many patients were discharged following transplant for follow-up care to private physicians' offices when engraftment of white blood cells had occurred, but often prior to achievement of platelet transfusion independence. Reliable data on platelet transfusions and short-term platelet engraftment were therefore not available for all patients. Patients routinely returned 6 to 8 weeks post-transplant for restaging evaluation.
PBPC mobilization
Ninety-eight patients received aggressive chemotherapy followed by filgrastim (Amgen, Thousands Oaks, CA, USA), 10-16 g/kg/day, for the dual purpose of treating the underlying malignancy, as well as to mobilize PBPC. A variety of chemotherapy regimens were used for mobilization ( Table 1 ). The most commonly used mobilizing regimen (DI-CE) included cyclophosphamide, 2.5 g/m 2 daily for 2 days and etoposide 150 mg/m 2 twice daily for 3 days. All patients receiving DI-CE for mobilization received prophylactic oral ciprofloxacin until resolution of neutropenia. PBPC collection was started when the white blood cell count recovered from a nadir to greater than 3000/mm 3 and/or when peripheral blood CD34 + cells were greater than 10/mm 3 . Filgrastim was continued until the last day of collection. The target PBPC cell collection was Ͼ5 ϫ 10 6 CD34 + cells/kg, however, after several days of pheresis, if greater than 2.0 ϫ 10 6 CD34 + cells/kg were collected, patients went on to receive high-dose chemotherapy rather than another course of mobilizing chemotherapy. Two patients undergoing syngeneic transplant received PBPC harvested from donors with filgrastim alone. During the initial 17 months of the study period, cells were collected through a tunneled double lumen permacatheter which was left in place throughout the transplant period. Because of difficulties with clotting and infection, temporary central lines or peripheral veins were preferred for pheresis in the latter 22 months of the study and subcutaneous portacatheters were used for venous access during the transplant period, if necessary. PBPC were reinfused through a peripheral intravenous line or a temporary central venous catheter was placed for reinfusion and then removed.
High-dose chemotherapy
BEAM chemotherapy was given over 6 days: BCNU: 300 mg/m 2 on day −6; etoposide: 200 mg/m 2 every 12 h, days −5 to −3; cytarabine 100 mg/m 2 every 12 h, days −5 to −2 and melphalan 140 mg/m 2 on day −1. The cumulative doses of the drugs were BCNU 300 mg/m 2 , etoposide 1200 mg/m 2 , cytarabine 800 mg/m 2 , melphalan 140 mg/m 2 . Doses were given according to the patient's actual weight except in patients whose weight was greater than 30% above their ideal body weight, in which case the body surface area was calculated according to the ideal body weight plus 30%. On day 0, PBPC were given through a central line by slow intravenous push. In patients who required several collections in order to achieve the target number of cells, infusions were sometimes given on 2 consecutive days in order to avoid the administration of an excessive volume of dimethylsulfoxide.
Supportive care
During the initial 22 months of the study period all patients were hospitalized for administration of high-dose chemotherapy and remained in the hospital until neutrophil engraftment occurred. On day 0, filgrastim, 5-10 g/kg subcutaneously, ciprofloxacin 500 mg p.o. twice daily and fluconazole 200 mg p.o. once daily were started and continued until engraftment. Acyclovir, 200 mg p.o. five times daily was administered to patients with positive HSV serology and/or a past history of HSV infection. Nine patients during the initial study period did not receive filgrastim post-transplant. During the second half of the study period all patients received 10 g/kg filgrastim. CMV-negative, irradiated blood products were given to all patients. Platelets were transfused for counts below 20 000/mm 3 or at higher counts if evidence of bleeding was present. Following cultures of the peripheral blood, central lines and urine, patients were given intravenous antibiotics for oral temperatures greater than 38.0°C or if the patient had chills or a change in clinical status suggestive of infection. Once intravenous antibiotics were started ciprofloxacin was discontinued, but fluconazole was maintained until the neutrophil count was greater than 500/mm 3 . The choice of initial empiric antibiotics was left to the discretion of the admitting physician and in the majority of cases included a combination of a third generation cephalosporin and gentamycin. Vancomycin was added initially if clinical evidence of a gram-positive infection was present or after 24-48 h for persistent fevers or positive cultures for gram positive organisms. During the latter half of the study, vancomycin was frequently included in the initial antibiotic regimen given the incidence of gram-positive infections during the initial study period.
Outpatient therapy
Beginning in January 1996, the entire treatment program was moved to the outpatient setting. To receive outpatient therapy patients had to have an available caretaker at home and live close enough to the hospital to arrive in a timely fashion for evaluation in the event of a fever or other difficulties post-transplant. Between January 1996 and the end of the study period, 49 patients were treated as outpatients. Nine patients failing to meet the above criteria were treated as inpatients during this time period. Outpatients received chemotherapy and were seen by a physician in the clinic during weekdays. Visiting nurses administered the remaining chemotherapy doses in the evenings and on weekends at the patient's home. PBPC were reinfused in the outpatient clinic and patients were then seen daily for blood work and examination starting on day + 2 until the time of WBC engraftment. Prophylactic oral antibiotics and filgrastim were administered to all patients as described above. Patients with an oral temperature greater than 38.0°C during the period of neutropenia were admitted for intravenous antibiotic therapy. Once daily ceftriaxone and once daily gentamicin were used as initial empiric intravenous antibiotics in most of these patients with the goal of early discharge with continued outpatient i.v. antibiotic therapy if cultures remained negative and the patient was clinically stable.
Definitions
Infectious episodes were classified into one of four groups: (1) microbiologically documented infection with bacteremia; (2) microbiologically documented infection without bacteremia; (3) clinically suspected infection without microbiological documentation; and (4) fever of unknown origin (FUO). Days to WBC engraftment were calculated from the day of PBPC infusion to the first of 3 consecutive days with an ANC Ͼ500/mm 3 . Platelet engraftment data were not collected as the majority of patients received care in referring physicians offices after neutrophil engraftment and hospital discharge, at which time some patients were still platelet transfusion-dependent.
Statistical methods
Data were analyzed using multivariate linear and logistic regressions in SAS (SAS Institute, Cary, NC, USA). The number of days of neutropenia and days to WBC engraftment were modeled as linear functions of patientrelated variables (age, disease type) and treatment covariates (filgrastim dose, CD34
+ cell dose, type of mobilizing regimen, number of cycles of prior therapy). A multivariate linear logistic regression model was used to test the association of filgrastim dose, CD34
+ cell dose, days of neutropenia, time to WBC engraftment, type of vascular access and treatment location with the occurrence of bacteremia or any infection. Statistical significance was defined as a P value Ͻ0.05.
Results
Infectious complications
Febrile neutropenia occurred in 68 patients and the median number of days with fever Ͼ38.0°C was 1 for the entire group. Thirty-four microbiologically documented infections occurred in 28 patients and included 15 episodes of bactere-mia in 14 patients ( Table 2 ). The most commonly isolated organism was coagulase-negative Staphylococci. No gramnegative infections occurred during the period of neutropenia although one patient developed a recurrent infection with Acinetobacter baumanni on day 0 (prior to the development of neutropenia) related to a previously infected portacatheter that had not been removed. No episodes of bacteremia occurred in the group of patients receiving 10 g/kg filgrastim and Ͼ10 ϫ 10 6 CD34 + cells/kg (n = 38). A variety of other infections was documented, the majority of which were minor. Among the more serious non-bacteremic infections were one patient with viral pneumonia (parainfluenza) and one patient with clinical findings consistent with typhilitis, both of whom recovered. A number of related factors was associated with the development of infection or bacteremia including the duration of neutropenia, time to WBC engraftment, number of PBPC infused, type of vascular access and treatment location (Table 3) . In a multivariate analysis, the risk of development of any infection was associated only with the duration of neutropenia (P = 0.02) and the risk of bacteremia was associated only with the number of CD34
+ cells infused (P = 0.046).
Morbidity and mortality
No intensive care unit hospitalization was required and no deaths occurred during the period of neutropenia or in the /kg infused were both negatively correlated with the duration of neutropenia (P Ͻ 0.0001), days to an ANC Ͼ500/mm 3 (P Ͻ 0.0001) and duration of hospitalization (P Ͻ 0.0001). The most rapid engraftment of WBC was observed in 38 patients receiving Ͼ10 CD34
+ cells ϫ 10 6 /kg and 10 g/kg filgrastim. The median duration of neutropenia and days to an ANC Ͼ500/mm 3 in this group were 5 and 8 days, respectively, and no patient took longer than 9 days to achieve neutrophil engraftment. As the majority of patients receiving Ͼ10 CD34 + cells ϫ 10 6 /kg also received 10 g/kg filgrastim, an analysis of the effect of filgrastim on WBC engraftment in patients receiving high numbers of CD34 + cells was not possible.
Outpatients
Forty-nine patients received treatment in the outpatient setting. Nine patients were treated as inpatients during the same time period because of concerns over compliance, distance from the hospital or lack of a caregiver at home. Comparative data for patients treated as inpatients and outpatients are presented in Table 5 . Characteristics of patients receiving therapy as outpatients were similar to those treated as inpatients. The majority of patients treated in the outpatient setting received a high dose of CD34 + cells/kg supported by 10 g/kg filgrastim and engrafted white blood cells promptly with very little variation. Only four of these patients had external-dwelling venous access devices during the transplant period. Sixty-five percent of outpatients developed febrile neutropenia and 71% of the group were admitted. Outpatients spent a median of 4.5 days in the hospital and 14 patients (28%) were never admitted.
Discussion
Few reports dedicated to the study of infectious outcomes following autologous PBPCT have been published. [3] [4] [5] In the present series, 100 patients received BEAM and PBPCT followed by a uniform antibiotic prophylactic regimen. Our objective was to develop a supportive care strategy which would allow the safe administration of high-dose therapy and subsequent follow-up in the outpatient setting. Since January 1996, 49 patients had high-dose BEAM administered in the clinic and at home with a decline in the average number of days of hospitalization from 19 to 4.5. Despite a liberal approach toward admission (fever Ͼ100.4°F, chills or failure to thrive) 14 patients (28%) did not require admission to the hospital. The major factors which facilitated this transfer of care included the predictably rapid engraftment of white blood cells provided by PBPC, effective prophylaxis against potentially life-threatening infections, especially aerobic gram-negative bacteria, and a lack of severe mucositis thus obviating the need for parenteral nutrition or large volume hydration. A number of factors were associated with the development of infection, although the duration of neutropenia, as noted in other reports, was the only variable retaining statistical significance in multivariate analysis. During the initial study period, the use of an external dwelling permacatheter, which was left in place from the time of mobilization of PBPC through the transplant, was associated with a high incidence of bacteremia (10 of the first 40 patients) and prompted a change in clinical practice to the use of temporary catheters. Nevertheless, the type of catheter used did not retain statistical significance in the multivariate analysis, possibly because the change in catheter use was accompanied by changes in other practices (PBPC dose, Patients were treated as outpatients during the latter half of the study period when there was a policy of using a higher dose of post-transplant filgrastim (10 g/kg) and a higher dose of CD34 + cells/kg. filgrastim dose) that may impact on the development of fever and infection. As in other studies, the use of hematopoietic growth factors and PBPC significantly reduced the duration of neutropenia compared with historical experiences with bone marrow. In the current group the median time to neutrophil engraftment (0.5 ϫ 10 9 /l) was 9 days. By comparison, using bone marrow without hematopoietic growth factors after BEAM, Mills et al 6 and Colombat et al 7 reported a median time to neutrophil engraftment of 21 and 20 days, respectively. Perhaps of greater importance was the narrow range in the time to engraftment in patients who received Ͼ10 ϫ 10 6 /kg CD34 + cells and 10 g/kg of filgrastim. In this group of patients the median duration of neutropenia was 5 days, no patient required more than 9 days to achieve neutrophil engraftment, and no episodes of bacteremia occurred. As patients with an expected duration of neutropenia of less than 7 days have been identified by others as being at low risk for serious morbidity from infection, 8, 9 it seems likely that an even greater proportion of care can be administered in the outpatient setting. 10, 11 The absence of neutropenic gram-negative infections, despite a relatively high incidence of febrile neutropenia is consistent with the findings of other studies in which prophylactic quinolone antibiotics have been used. [12] [13] [14] [15] Although the etiology of fever in many of these patients remains obscure, we believe that the low incidence of gram-negative infections may be especially important in patients treated in the outpatient setting, where there may be a longer period of time between signs and symptoms of an infection and the administration of (additional) antibiotic treatment. Nevertheless, given the concerns over the emergence of quinolone-resistant bacteria, and the absence of data supporting a reduction in mortality in patients given prophylactic antibiotics, this point will have to be tested in randomized trials. [16] [17] [18] [19] [20] [21] [22] A major factor which facilitated the transfer of care to the outpatient setting was the lack of severe mucositis after BEAM chemotherapy, administered at the current doses. In contrast, Mills et al 6 described nearly universal pan mucositis, and three-quarters of the patients required narcotic analgesia and TPN. In these reports the dose of cytarabine ranged from 800-1600 mg/m 2 compared with the current study, in which the VP-16 and cytarabine doses were 1200 mg/m 2 and 800 mg/m 2 , respectively. Chopra et al 23 reported a 10% treatment-related mortality including 5.6% in the first 21 days in a study in which 90% of the patients received doses of VP-16 and cytarabine of 1600 mg/m 2 and 800 mg/m 2 , respectively. Interestingly, in these studies prophylactic antibiotics were not used in the majority of patients and growth factors, which have been shown in some studies to reduce the duration of mucositis, were used in only a few patients. The lack of mucositis may have impacted on the incidence of infection, particularly Strep viridans bacteremia, which may result in significant morbidity following high-dose cytarabine. Thus, it may not be possible to extrapolate our results to other regimens in which severe mucositis is common, such as radiation-based programs, or versions of BEAM in which higher doses of cytarabine are used. In view of the lack of demonstrable superiority of a regimen in which higher doses of cytarabine and VP-16 are used, we have elected to continue the doses used in the current study.
In summary, we have reported a low incidence of infections and no acute mortality in 100 patients with NHL and Hodgkin's disease who were treated with high-dose BEAM chemotherapy followed by PBPCT, filgrastim and a uniform strategy of antibiotic prophylaxis. The low incidence of severe toxicity or serious infections in the initial patients has allowed all of the treatment and most of the follow-up to be transferred to the outpatient setting. Future directions will include comparing the use of prophylactic antibiotics vs the use of oral broad spectrum antibiotics at the time of fever. It also seems likely, given the brief duration of neutropenia, that antifungal prophylaxis may be unnecessary.
